HGH means human growth hormone. Prescription somatropin supplies a manufactured version of that hormone. Sermorelin instead signals the pituitary to release growth hormone; it does not supply the hormone directly.
Neither description tells you whether treatment is appropriate. In adults, established growth hormone deficiency is a medical diagnosis. Feeling tired or noticing age-related changes is not enough to establish it, and a marketing comparison cannot replace an endocrine evaluation.
Sermorelin stimulates a pathway; somatropin supplies growth hormone. They are not dose-for-dose substitutes.
Why the diagnosis comes before the product
The Endocrine Society's adult deficiency guideline describes evaluation in an appropriate clinical context, often including stimulation testing. A clinician may consider pituitary disease, prior surgery or radiation, and other hormone deficiencies. The question is more specific than whether a number looks lower than that of a younger adult.
Do not assume that a single random growth hormone measurement answers the question. Hormone secretion varies, and laboratory interpretation belongs within the full assessment. The labs and IGF-1 guide explains why a marker is not a diagnosis by itself.
Why stimulation may not equal replacement
A medicine that asks the pituitary to respond depends on the relevant pathway's function. Supplying growth hormone directly is a different intervention. That distinction is one reason a prescriber should explain the diagnosis and treatment rationale rather than describe one option as a universally gentler substitute.
Comparative claims also need to identify the actual formulation. Historical GEREF approval does not make today's compounded sermorelin equivalent to an FDA-approved somatropin product. Read the sermorelin approval history before treating ingredient history as finished-product evidence.
A natural signal can still produce unwanted effects
Encouraging the body to release a hormone does not place the treatment outside pharmacology. Changes in hormone activity can have consequences, and compounded preparations add questions about strength, quality, and handling. “Natural” is therefore not a substitute for an adverse-effect discussion.
Ask what symptoms and laboratory findings would lead to reassessment, who reviews follow-up results, and how to contact the team. A claim of fewer risks requires a meaningful comparison in relevant patients; it should not be accepted merely because one treatment is described as stimulation and the other as replacement.
For anti-aging goals, widen the conversation
Studies of hormone-related interventions in older adults do not establish a universal anti-aging program. Changes in lean mass are not identical to improved strength, mobility, or independence. Costs and treatment burden also matter when meaningful benefit is uncertain.
If the goal is better functioning, start with the actual limitation and ask what interventions have evidence for it. Our after-50 guide and muscle-growth article help separate a reasonable clinical question from promises of reversing aging.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- Endocrine Society: Adult growth hormone deficiencyClinical practice guideline · Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.
- Sigalos and Pastuszak: Safety and efficacy of growth hormone secretagoguesClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- FDA: 2013 GEREF withdrawal determinationFederal Register / FDA · Historical GEREF products were not withdrawn for safety or effectiveness reasons; this does not approve current compounds.
- FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
- Endotext: Growth Hormone and AgingExpert clinical evidence review · Separates hormone and body-composition findings from functional outcomes and long-term unknowns.